BlackRock Health Sciences Trust II Ratios | P/E, ROE & Valuation

On the Key Ratios page for BlackRock Health Sciences Trust II (BMEZ), the latest P/E of 9.5 frames valuation, while ROE 3.46% and ROIC 0.12% indicates profitability and capital efficiency. Together with the current ratio of 0.00 and debt-to-equity 0.00, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

BMEZ Historical Per Share Metrics

7 years
Metric (FY)TTM202420232022202120202019
Revenue per Share$1.82$1.82$0.59$-2.06$0.53$0.05$0.00
Net Income per Share$1.77$1.77$1.44$-2.10$0.52$0.71$0.00
Operating Cash Flow per Share$4.94$4.94$2.30$-0.07$-0.19$-0.17$-13.44
Free Cash Flow per Share$4.94$4.94$2.30$-0.07$-0.19$-0.17$-13.44
Cash per Share$2.00$2.00$0.00$0.00$0.00$0.00$0.00
Book Value per Share$57.98$57.98$42.18$47.61$5.54$4.84$14.52
Tangible Book Value per Share$57.98$57.98$42.18$47.61$5.54$4.84$14.52
Interest Debt per Share$0.02$0.02$0.00$0.05$0.00$0.00$0.00
CAPEX per Share$0.00$0.00$0.00$0.00$0.00$0.00$0.00

BMEZ Historical Valuation Ratios

7 years
Metric (FY)TTM202420232022202120202019
Price to Earnings (P/E)9.538.1410.21-7.3548.4240.580
Price to Book (P/B)0.290.250.350.324.571.071.38
Price to Sales (P/S)70.967.9324.93-7.4947.98615.990
Enterprise Value to EBITDA1842.568.1310.2-7.3748.4300
EV to Sales70.977.9424.94-7.5247.99615.970
EV to Operating Cash Flow26.072.926.38-223.3-132.81-166.85-1.49
EV to Free Cash Flow26.072.926.38-223.3-132.81-166.85-1.49
Enterprise Value$1.71B$191.09M$204.34M$195.18M$2.86B$3.23B$2.26B

BMEZ Historical Profitability Ratios

7 years
Metric (FY)TTM202420232022202120202019
Return on Equity (ROE)3.46%3.05%3.40%-4.41%9.45%2.63%0.00%
Return on Invested Capital (ROIC)0.12%0.12%1.42%0.25%0.01%-0.00%0.00%
Return on Tangible Assets3.03%3.03%3.36%-4.37%9.11%14.35%0.00%
Earnings Yield10.49%12.29%9.80%-13.61%2.07%2.46%0.00%
Free Cash Flow Yield3.84%34.33%15.67%-0.45%-0.75%-0.60%-67.08%
Dividend Yield8.14%18.82%17.18%16.83%1.01%0.79%0.00%

BMEZ Historical Liquidity & Financial Strength

7 years
Metric (FY)TTM202420232022202120202019
Current Ratio000000.050.71
Interest Coverage11886.8711886.87153893.450000
Income Quality2.792.791.60.03-0.36-0.24-13.38
Debt to Equity0000000
Debt to Assets0.04%0.04%0.01%0.11%0.03%0.02%0.00%
Net Debt to EBITDA0.220.010-0.03000

BMEZ Historical Efficiency Ratios

7 years
Metric (FY)TTM202420232022202120202019
Receivables Turnover20.1420.145.2-10.9718.7713.950
Payables Turnover0000000
Inventory Turnover0000000
Days Sales Outstanding18.1318.1370.24-33.2919.4426.160
Days Payables Outstanding0000000
Days of Inventory on Hand0000000

BMEZ Historical Market Metrics

7 years
Metric (FY)TTM202420232022202120202019
Enterprise Value to EBITDA1842.568.1310.2-7.3748.4300
Market Cap$1.71B$190.88M$204.28M$194.50M$2.86B$3.23B$2.26B
Enterprise Value$1.71B$191.09M$204.34M$195.18M$2.86B$3.23B$2.26B
Dividend Yield8.14%18.82%17.18%16.83%1.01%0.79%0.00%
Payout Ratio153.16%153.16%175.35%-123.63%49.06%32.24%0.00%

Frequently Asked Questions

How does BlackRock Health Sciences Trust II’s P/E ratio compare with its history?

On this page, BMEZ's current P/E is 9.5, compared with a multi-year average around 23.4. A lower P/E versus its own history is a calculated gap versus that average—not a conclusion that the stock is cheap. Pair it with profitability and earnings quality in the table (for example ROE/ROIC) to see whether the multiple moved with earnings.

What is BlackRock Health Sciences Trust II market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $1.71B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does BlackRock Health Sciences Trust II’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with BlackRock Health Sciences Trust II's own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does BlackRock Health Sciences Trust II compare to its competitors in key financial ratios?

The fastest way to compare BlackRock Health Sciences Trust II with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see BlackRock Health Sciences Trust II outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do BlackRock Health Sciences Trust II's liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that BlackRock Health Sciences Trust II is financially strong. Current ratio is about 0.00, which is below 1.0 and can suggest tighter short-term liquidity. Interest coverage is about 11886.87, implying a stronger ability to cover interest expenses. Debt-to-equity is about 0.00, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do BlackRock Health Sciences Trust II's financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If BlackRock Health Sciences Trust II is sustaining strong returns (for example ROE at 3.46% and ROIC at 0.12%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.